Non-Hodgkin Lymphoma Therapeutics Market Updates

Skyquest Technology's expert advisors continuously track and analyze the latest developments and updates related to non-hodgkin lymphoma therapeutics market. Our team of analysts stay abreast of all the recent news stories shaping the industry including new product launches by major companies, strategic partnerships, M&As, Patent filings and industry and regulatory developments.

Non-Hodgkin Lymphoma Therapeutics Market News

in Non-Hodgkin Lymphoma Therapeutics Market
  • In April 2024, Roche announced that its bispecific antibody, Columvi (glofitamab), met the primary endpoint in a Phase 3 trial for relapsed or refractory diffuse large B-cell lymphoma (DLBCL). The combination of Columvi with chemotherapy significantly improved overall survival in patients not eligible for stem cell transplants. The safety profile was consistent with known data from individual medicines.
  • In May 2024, The U.S. FDA granted approval to Bristol Myers Squibb's CAR T-cell therapy, Breyanzi (lisocabtagene maraleucel), for treating adults with relapsed or refractory follicular lymphoma after at least two prior therapies. This approval expands Breyanzi's use, making it the only CAR T-cell therapy approved for four distinct subtypes of NHL, offering new hope for patients with B-cell malignancies.
  • In August 2024, Incyte announced that its blood cancer drug, Monjuvi, achieved the primary goal in a late-stage trial for treating patients with follicular lymphoma, a form of NHL. When combined with Bristol Myers Squibb's Revlimid and Biogen's Rituxan, Monjuvi improved progression-free survival compared to the combination of Rituxan and Revlimid alone. These positive results pave the way for a supplemental FDA application by year-end.
REPORT OVERVIEW BUY NOW

REQUEST FOR SAMPLE

Want to customize this report? REQUEST FREE CUSTOMIZATION

FAQs

Global Non-Hodgkin Lymphoma Therapeutics Market size was valued at USD 4.37 Billion in 2023 poised to grow from USD 4.62 Billion in 2024 to USD 7.20 Billion by 2032, growing at a CAGR of 5.7% in the forecast period (2025-2032).

The global non-hodgkin lymphoma therapeutics market outlook is highly competitive, with leading players such as Roche, Novartis, Gilead Sciences, and Bristol-Myers Squibb dominating the landscape. These companies focus on innovative therapies, including immunotherapies and CAR-T cell treatments. Roche utilizes strategic collaborations and investments in R&D to expand its portfolio, while Gilead Sciences emphasizes acquiring smaller biotech firms to enhance its treatment offerings and strengthen its market position. 'Roche (Switzerland)', 'Novartis (Switzerland)', 'Gilead Sciences (USA)', 'Bristol-Myers Squibb (USA)', 'AbbVie (USA)', 'Merck & Co. (USA)', 'Celgene Corporation (USA)', 'Amgen (USA)', 'Pfizer (USA)', 'Eli Lilly and Co. (USA)', 'Johnson & Johnson (USA)', 'AstraZeneca (United Kingdom)', 'Sanofi (France)', 'Bayer AG (Germany)', 'Genmab (Denmark)'

The increasing incidence of non-hodgkin lymphoma, driven by aging populations and lifestyle factors, is a key driver for the global non-hodgkin lymphoma therapeutics market trends. As more individuals are diagnosed, there is a greater demand for innovative treatment options, such as immunotherapies, chemotherapy, and targeted therapies, fostering market growth.

Growth of Immunotherapy Approaches in NHL Treatment: Immunotherapy, especially CAR-T cell therapy, is emerging as a significant trend in the non-hodgkin lymphoma therapeutics market. These therapies harness the body’s immune system to target lymphoma cells, offering promising treatment outcomes for patients with relapsed or refractory lymphoma, driving market growth.

What Role do Emission Regulations Play in North American Demand?

Request Free Customization

Want to customize this report? This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time. We offer $1000 worth of FREE customization at the time of purchase.

Click here right-arrow
logo-images

Feedback From Our Clients

Global Non-Hodgkin Lymphoma Therapeutics Market
Non-Hodgkin Lymphoma Therapeutics Market

Report ID: SQMIG35D2307

[email protected]
USA +1 351-333-4748

BUY NOW GET FREE SAMPLE